hyperCORE International

Phase 1

Questions?

Phase 1 Capabilities

Nine Phase 1 capable sites in 14 locations in the United States and Canada with 23 Principal Investigators

Collectively conducted 55 Phase 1 trials - 21 were first-in human trials

Overnight capabilities in 8 locations with 107 beds combined. Facilities range from 4,000 to 17,000 SF

On-site pharmacies at 6 sites; PBMC capabilities at 5 sites

Over 2.8 million patients in collective databases; diversity recruitment in Hispanic, Asian, and Black communities

Phase 1 Therapeutics

Endocrinology
Vaccine Capabilities
Gerontology
Ophthalmology
Gynecology
Nephrology
NASH Capabilities
Oncology
Rheumatology
Psychiatry
Podiatry
Dermatology Capabilities
Hematology
Cardiology
Pulmonology
Pain Management
COVID- 19 Capabilities
Pediatrics
Urology
Devices / Diagnostics
Neurology
Cannabis & Psychedelics
Smoking Cessation
Gastroenterology
Men’s Health
Nutrition
Immunology

Phase 1 Testing / Equipment